Fennec Pharmaceuticals Inc is a biotechnology business based in the US. Fennec Pharmaceuticals shares (FENC) are listed on the NASDAQ and all prices are listed in US Dollars. Fennec Pharmaceuticals employs 9 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $4.60 |
|---|---|
| 52-week range | $3.82 - $10.08 |
| 50-day moving average | $6.03 |
| 200-day moving average | $7.08 |
| Wall St. target price | $10.80 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.63 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.6 from 2022-01-18
| 1 week (2022-01-12) | -3.06% |
|---|---|
| 1 month (2021-12-17) | 12.75% |
| 3 months (2021-10-19) | -48.26% |
| 6 months (2021-07-19) | -29.66% |
| 1 year (2021-01-19) | -41.85% |
|---|---|
| 2 years (2020-01-17) | -25.57% |
| 3 years (2019-01-18) | 6.98 |
| 5 years (2017-01-19) | 135.90% |
| Revenue TTM | $170,000 |
|---|---|
| Gross profit TTM | $170,000 |
| Return on assets TTM | -34.04% |
| Return on equity TTM | -64.37% |
| Profit margin | 0% |
| Book value | $0.73 |
| Market capitalisation | $120.4 million |
TTM: trailing 12 months
We're not expecting Fennec Pharmaceuticals to pay a dividend over the next 12 months.
Fennec Pharmaceuticals's shares were split on a 1:3 basis on 4 September 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Fennec Pharmaceuticals shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Fennec Pharmaceuticals shares which in turn could have impacted Fennec Pharmaceuticals's share price.
Over the last 12 months, Fennec Pharmaceuticals's shares have ranged in value from as little as $3.822 up to $10.078. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fennec Pharmaceuticals's is 0.0588. This would suggest that Fennec Pharmaceuticals's shares are less volatile than average (for this exchange).
Fennec Pharmaceuticals Inc. , a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.